Artivion Secures FDA PMA Approval Of PerClot And Transfer Of PMA To Baxter
Portfolio Pulse from Benzinga Newsdesk
Artivion has secured FDA PMA approval for PerClot and will transfer the PMA to Baxter. Artivion will receive a milestone payment of $18.75 million, with $4.5 million paid to its former partner Starch Medical, Inc.
May 23, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Artivion secures FDA PMA approval for PerClot, leading to a milestone payment of $18.75 million.
The FDA PMA approval for PerClot is a significant milestone for Artivion, as it will lead to a cash inflow of $18.75 million. This will likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Baxter will receive the PMA for PerClot from Artivion following FDA approval.
Baxter will receive the PMA for PerClot from Artivion, which could potentially expand its product portfolio and enhance its market position. This may have a positive impact on Baxter's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 80